A Case of MSI-H Ascending Colon Cancer which Achieved a Pathological CR after Pembrolizumab Administration
Author:
Affiliation:
1. Department of Surgery, Ashikaga Red Cross Hospital
2. Department of Diagnostic Pathology, Ashikaga Red Cross Hospital
Publisher
Japan Surgical Association
Subject
General Engineering
Link
https://www.jstage.jst.go.jp/article/jjsa/84/6/84_911/_pdf
Reference8 articles.
1. 1) De Roock W, De Vriendt V, Normanno N, et al : KRAS, BRAF, PIK3CA, and PTEAN mutations : implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011 ; 12 : 594-603
2. 2) Van Cutsem E, Köahne CH, Láng I, et al : Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer : updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2010 ; 29 : 2011-2019
3. 3) Lamy A, Blanchard F, Le Pessot F, et al : Metastatic colorectal cancer KRAS genotyping in routine practice : results and pitfalls. Mod Pathol 2011 ; 24 : 1090-1100
4. 4) Cremolini C, Loupakis F, Antoniotti C, et al : FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer : updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015 ; 16 : 1306-1315
5. 5) 山口研成，篠崎英司，下嵜啓太郎他:大腸癌の化学療法．医と薬学 2022;79:113-116
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3